Reflections on SSIEM annual symposium 2019 – Building Bridges

Reflections on SSIEM annual symposium 2019 – Building Bridges   Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the annual symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM): Having returned from this year’s...

New Year brings new look at khondrion.com

Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the launch of its new website.As the company continues to advance its proprietary science through a wholly-owned clinical and...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the Netherlands – November 2018: Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies...